Skip to main content

Table 1 The polymerase chain reaction (PCR) primers and homogeneous Mass EXTEND (hME) primers of 22 single nucleotide polymorphisms (SNPs) in three candidate genes

From: Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer

Gene

Localization

SNP

PCR primer (5′ → 3′)

hME primer (5′ → 3′)

TYMS

18p11.32

2790

First: ACGTTGGATGGGATGCCGAGGTAAAAGTTC

GATTTTTGACCTAGTTCCTT

Second: ACGTTGGATGAACTGATAGGTCACGGACAG

 

2,853,741

First: ACGTTGGATGGGAAACAGATCTCAAACAGC

GGTACCACGTTTTCCTGCGGTCTTGTC

Second: ACGTTGGATGAGCACAGTTCCCACGTTTTC

 

2,606,241

First: ACGTTGGATGCCACAGCTGAGAGTCTTAGG

GGGCGCAGTCCTTCCC

Second: ACGTTGGATGACCAGACGGTTCCCAAAGG

 

3,786,362

First: ACGTTGGATGTTGGACAGCCTGGGATTCTC

GCCCAAGTCCCCTTC

Second: ACGTTGGATGCAAAATGCCTCCACTGGAAG

 

1,004,474

First: ACGTTGGATGTAAAACTGTGACTCTCCCCC

GACCTCAGATGGTGATGTTCGTCTA

Second: ACGTTGGATGGGGAAAGGCTGACATACATC

 

9,947,507

First: ACGTTGGATGAATTCTTCTGCCTCAGCCTC

GCCCCCGTCTCTACTAAAA

Second: ACGTTGGATGTGGACAACATGGTGAAACCC

 

699,517

First: ACGTTGGATGCCACTGAAGAACCCTAAAAG

GGAGAAAGACTGACAATATCCTTC

Second: ACGTTGGATGACTTTTACCTCGGCATCCAG

 

9,967,368

First: ACGTTGGATGTGGGTGACAGAGCCGTATG

AACCCAGATATTCCTTTCTATT

Second: ACGTTGGATGGAATCCATGGTCTCCACAAC

 

15,872

First: ACGTTGGATGACAGAACTACACTACCAAGG

CCCCCCTCTCATGGTCACTGTTCC

Second: ACGTTGGATGGAAAGTCCTCTCATGGTCAC

 

MTHFR

1p36.3

1,801,133

First: ACGTTGGATGCTTGAAGGAGAAGGTGTCTG

AACGCGTGATGATGAAATCG

Second: ACGTTGGATGTGCATGCCTTCACAAAGCGG

 

1,801,131

First: ACGTTGGATGTCTCCCGAGAGGTAAAGAAC

CATGAGCTGACCAGTGAAG

Second: ACGTTGGATGAGGAGCTGCTGAAGATGTGG

 

3,737,964

First: ACGTTGGATGTGATGGCTGTAGATCCTCAC

GCAGCCCTCAAAAAAAACCTTTC

Second: ACGTTGGATGTCAAATAGGAACCAGCCCTC

 

4,846,049

First: ACGTTGGATGAACTAAGCCCTCGAACCAAG

TGCACGGGCTCCAAG

Second: ACGTTGGATGTGTTTTGCCTGTACTGCACG

 

2,274,976

First: ACGTTGGATGTATGTGTGTGTAGGACGAGG

CATACAGCTTTCCCCAC

Second: ACGTTGGATGATGTACTGGATGATGGTGCG

 

3,753,582

First: ACGTTGGATGACGCAGTGGGCGCCAGGGA

CTCATTTTAAACCTGCCTCCCCGGCGA

Second: ACGTTGGATGTGCCTTTTAAACCTGCCTCC

 

4,846,048

First: ACGTTGGATGTTTGGTTTGGTGGTGGCTTC

GGAATCAGTTAGTTCTGACACCAACAA

Second: ACGTTGGATGTCCAGACCAGAAGCAGTTAG

 

RRM1

11p15.5

725,519

First: ACGTTGGATGCACTTTAACTCTAGAAGATTG

TGGTGAAGAAATATGTAATGCCTCA

Second: ACGTTGGATGGCCTAGCATATAAAGTGCTC

 

720,106

First: ACGTTGGATGGCAGTAATAAGAGCAGTTATC

AAACATTTATAACAAACTTAACATAC

Second: ACGTTGGATGAAGGGTCAAATGAGTACCTC

 

1,042,858

First: ACGTTGGATGAGGGTTTGAAGACTGGGATG

GAACTGGATTGGATTAGC

Second: ACGTTGGATGGCTTCTCCTTATTTAGAGTG

 

1,042,927

First: ACGTTGGATGCCACCAGTCAAAGCAGTAAA

GGTAAGTAAGGTTTCATCACCC

Second: ACGTTGGATGCAGGGAGTGGTTAAGTAAGG

 

11,030,918

First: ACGTTGGATGTCCTGACGCAAATCAGAGCC

GGCTTACCCTGCCCTGCTTAAAAT

Second: ACGTTGGATGCCACTGAAGAACCCTAAAAG

 

1,980,412

First: ACGTTGGATGGGTCTTCAGAACTATGAGAG

GGGCCAAAGGTATTTAAGTTTCCTATG

Second: ACGTTGGATGCCAGAGGACAAAGGTATTTA

 
  1. TYMS thymidylate synthase, MTHFR methylene tetrahydrofolate reductase, RRM1 ribonucleotide reductase M1
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us